Short‐Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States
Open Access
- 3 March 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e043588
Abstract
Background: Heart transplant (HT) and left ventricular assist devices (LVADs) are treatment options for advanced heart failure refractory to standard therapy. Historically, LVADs have been used as either destination therapy or a bridge to transplant. However, recent changes to the organ allocation system have deprioritized patients on LVADs as transplant recipients, leading to divisive views on the role of an LVAD. The comparative short‐term care burden with each modality remains unclear. Methods: We aimed to describe and compare characteristics, outcomes, and cost burden during index hospitalizations and 30‐day and 90‐day readmissions associated with HTs and durable LVADs from a large, national administrative database. A review of the Nationwide Readmissions Database from 2018 to 2021 describing a cohort identified using International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ) procedure codes: 02YA0Z0 and 02HA0QZ. Results: We identified 27 308 index hospital admissions; 52.4% received LVADs, and the remainder received HTs. Compared with HT recipients, LVAD recipients were older and more likely male, of lower socioeconomic status, had longer index hospital stays, and had more expensive index hospitalizations. A higher proportion of LVAD recipients required rehospitalization in 30 days. The most frequent causes of rehospitalization in the LVAD group at both 30 and 90 days were heart failure, device complications, and gastrointestinal bleeding. The most frequent causes in the HT group at 30 and 90 days were transplant complications, renal dysfunction, and sepsis (at 90 days only). Thirty‐ and 90‐day rehospitalization costs were greater in the HT group. Conclusions: Both LVAD and HT had comparable burdens on resources and short‐term rehospitalization risk.Keywords
This publication has 23 references indexed in Scilit:
- Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist DevicesJACC: Heart Failure, 2024
- Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart FailureJAMA, 2023
- Impact of the 2018 UNOS Heart Transplant Policy Changes on Patient OutcomesJACC: Heart Failure, 2023
- Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized TrialJAMA, 2022
- Center Variability in Patient Outcomes Following HeartMate 3 Implantation: An Analysis of the MOMENTUM 3 TrialJournal of Cardiac Failure, 2022
- Medicaid Expansion and Ventricular Assist Device ImplantationJACC, 2020
- Racial Disparities and Outcomes of Left Ventricular Assist Device Implantation as a Bridge to Heart TransplantationESC Heart Failure, 2020
- Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist DevicesJAMA Cardiology, 2020
- Clinical Outcomes After Left Ventricular Assist Device Implantation in Older AdultsJACC: Heart Failure, 2019
- Effects of socioeconomic status on clinical outcomes with ventricular assist devicesClinical Cardiology, 2018